MedTrace Logo

Onvansertib + Paclitaxel In TNBC

NCT05383196 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-02-11

No results posted yet for this study

Summary

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body.

The names of the study interventions involved in this study are:

* Onvansertib
* Paclitaxel

Conditions

Interventions

DRUG

Onvansertib

oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.

DRUG

Paclitaxel

once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle

Sponsors & Collaborators

  • Cardiff Oncology

    collaborator INDUSTRY

  • Antonio Giordano, MD

    lead OTHER

Principal Investigators

  • Antonio C Giordano, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2026-12-15
Completion
2029-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05383196 on ClinicalTrials.gov